Ovid Therapeutics Inc.

NasdaqGS:OVID Stock Report

Market Cap: US$70.9m

Ovid Therapeutics Management

Management criteria checks 3/4

Ovid Therapeutics' CEO is Jeremy Levin, appointed in Mar 2015, has a tenure of 9.75 years. total yearly compensation is $2.14M, comprised of 29.3% salary and 70.7% bonuses, including company stock and options. directly owns 5.14% of the company’s shares, worth $3.65M. The average tenure of the management team and the board of directors is 3.4 years and 3.4 years respectively.

Key information

Jeremy Levin

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage29.3%
CEO tenure9.8yrs
CEO ownership5.1%
Management average tenure3.4yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 09

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Nov 10
We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Jun 27
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Mar 13
Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Sep 09
Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

Aug 09

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Jun 09
We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Ovid Therapeutics: Good Entry Point For Investors

Jun 18

Ovid Therapeutics appoints Jeff Rona as CFO

Jun 04

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Apr 16
Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Mar 20
Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 18
Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Mar 01
We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Jan 25
Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Revisiting Ovid Therapeutics

Jan 14

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Dec 21
Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Ovid Therapeutics misses goal in Angelman syndrome treatment

Dec 01

CEO Compensation Analysis

How has Jeremy Levin's remuneration changed compared to Ovid Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$33m

Jun 30 2024n/an/a

-US$30m

Mar 31 2024n/an/a

-US$51m

Dec 31 2023US$2mUS$625k

-US$52m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$51m

Dec 31 2022US$3mUS$607k

-US$54m

Sep 30 2022n/an/a

-US$68m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$847kUS$584k

US$120m

Sep 30 2021n/an/a

US$123m

Jun 30 2021n/an/a

US$117m

Mar 31 2021n/an/a

US$110m

Dec 31 2020US$2mUS$560k

-US$81m

Sep 30 2020n/an/a

-US$76m

Jun 30 2020n/an/a

-US$76m

Mar 31 2020n/an/a

-US$67m

Dec 31 2019US$3mUS$530k

-US$60m

Sep 30 2019n/an/a

-US$56m

Jun 30 2019n/an/a

-US$53m

Mar 31 2019n/an/a

-US$53m

Dec 31 2018US$3mUS$530k

-US$52m

Sep 30 2018n/an/a

-US$50m

Jun 30 2018n/an/a

-US$46m

Mar 31 2018n/an/a

-US$44m

Dec 31 2017US$2mUS$515k

-US$65m

Compensation vs Market: Jeremy's total compensation ($USD2.14M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Jeremy's compensation has been consistent with company performance over the past year.

CEO

Jeremy Levin (71 yo)

9.8yrs

Tenure

US$2,136,546

Compensation

Dr. Jeremy Max Levin, M.D., Ph D., BA Zoology, DPhil, MB BChir, serves as Director of Graviton BioScience Corporation from May 2023. He is Member of Advisory Board at New Rhein Healthcare Investors LLC.He...

Leadership Team

NamePositionTenureCompensationOwnership
Jeremy Levin
CEO & Chairman9.8yrsUS$2.14m5.14%
$ 3.6m
Jeffrey Rona
Chief Business and Financial Officer3.5yrsUS$1.08m0.019%
$ 13.7k
Meg Alexander
President & COOless than a yearno datano data
Dirk Haasner
Senior Vice President of Global Manufacturing & CMC QA8.8yrsUS$1.18mno data
Julia Tsai
Senior Vice President of Clinical Development3.4yrsno datano data
Toshiya Nishi
Head of Epilepsy Research1.8yrsno datano data
Zhong Zhong
Chief Scientific Officer1.5yrsno datano data
Tom Parry
Vice President of Research and Early Developmentno datano datano data
Garret Bonney
Investor Relations Officerno datano datano data

3.4yrs

Average Tenure

57.5yo

Average Age

Experienced Management: OVID's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jeremy Levin
CEO & Chairman10.7yrsUS$2.14m5.14%
$ 3.6m
Robert S. Langer
Chairman of the Scientific & Clinical Advisory Board3.7yrsno datano data
Barbara Duncan
Independent Director7.5yrsUS$86.66k0%
$ 0
Bart Friedman
Lead Independent Director9.1yrsUS$104.16k0%
$ 0
Jacqueline A. French
Member of Scientific & Clinical Advisory Board7.9yrsno datano data
Karen Bernstein
Independent Director9.3yrsUS$91.66k0.028%
$ 20.0k
Raman Sankar
Member of Scientific Advisory Boardless than a yearno datano data
Kevin Fitzgerald
Independent Director3.2yrsUS$71.66k0%
$ 0
Jeffrey Noebels
Member of Scientific Advisory Boardless than a yearno datano data
Imad Najm
Member of Scientific Advisory Boardless than a yearno datano data
Jamie Maguire
Member of Scientific Advisory Boardless than a yearno datano data
Isam Awad
Member of Scientific Advisory Boardless than a yearno datano data

3.4yrs

Average Tenure

71yo

Average Age

Experienced Board: OVID's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:56
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ovid Therapeutics Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
Thomas ShraderBTIG
Charles DuncanCantor Fitzgerald & Co.